Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Product prescribing issue? 5 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Product prescribing issue have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.0% of all adverse event reports for TOCILIZUMAB.

5
Reports of Product prescribing issue with TOCILIZUMAB
0.0%
of all TOCILIZUMAB reports
1
Deaths
1
Hospitalizations

How Dangerous Is Product prescribing issue From TOCILIZUMAB?

Of the 5 reports, 1 (20.0%) resulted in death, 1 (20.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.

Is Product prescribing issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Product prescribing issue?

DUPILUMAB (1,715) POLYETHYLENE GLYCOL 3350 (1,439) LENALIDOMIDE (948) OXYCODONE (646) RIVAROXABAN (359) ACETAMINOPHEN\OXYCODONE (347) ETONOGESTREL (311) ACETAMINOPHEN\HYDROCODONE (298) CERTOLIZUMAB PEGOL (297) CABOZANTINIB S-MALATE (294)

Which TOCILIZUMAB Alternatives Have Lower Product prescribing issue Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Product prescribing issue Reports All Drugs Causing Product prescribing issue TOCILIZUMAB Demographics